H.C. Wainwright analyst Andrew Fein said he recognizes that the small market cap of Cyclacel Pharmaceuticals keeps the stock from being appetizing to some investors, but he sees an "atypically positive risk/reward" ahead of its pending readout of a study in elderly acute myeloid leukemia patients unfit for induction therapy. An outright survival win in the study "may be a long shot," but the "surprise element" in AML can go both ways, Fein tells investors. Even without AML, Cyclacel is attractive based on its other two clinical programs, said the analyst, who has a $60 price target on the shares and thinks the stock could have a $173 per share full value if there were to be a topline win in AML.